# Curis, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Curis, Inc). ## Overview Curis Inc. is a U.S.-based biotechnology company focused on developing emavusertib (CA-4948), an oral small-molecule inhibitor of IRAK4. Its business model is centered on advancing this single lead asset through clinical trials and, if successful, partnering or licensing the program to a larger pharmaceutical company for commercialization. The company does not expect meaningful direct product sales in the near term and instead relies on collaboration-related cash flows and royalty revenue tied to Genentech’s commercialization of Erivedge. Curis also has a royalty monetization structure in place through its 2019 agreement with Oberland Capital, which diverts a portion of future royalty receipts in exchange for upfront funding. ## Products & services • Emavusertib (CA-4948) clinical development • IRAK4 inhibitor oncology program • TakeAim Lymphoma Phase 1/2 study • TakeAim Leukemia Phase 1/2 study • Royalty rights from Erivedge collaboration • Collaboration and licensing of drug candidates - **Clinical-stage drug development** (0%) — Development of emavusertib through preclinical and clinical oncology studies. - **Collaborative R&D and licensing** (0%) — Partnering, licensing, and milestone-based arrangements for drug candidates. - **Royalty income** (100%) — Royalty receipts from Genentech/Roche sales of Erivedge under the collaboration agreement. - Emavusertib (CA-4948) clinical development - IRAK4 inhibitor oncology program - TakeAim Lymphoma Phase 1/2 study - TakeAim Leukemia Phase 1/2 study - Royalty rights from Erivedge collaboration - Collaboration and licensing of drug candidates ## Customers Curis does not sell commercial products directly to patients or hospitals; its economic counterparties are primarily pharmaceutical collaborators and licensees. The most important external revenue source described in the filings is Genentech, whose Erivedge sales generate royalty income for Curis under the collaboration agreement. The company also seeks future partners that could license emavusertib and help fund late-stage development and commercialization. In practice, Curis’s “customers” are therefore strategic pharma partners rather than end users, and their willingness to continue development or pay royalties determines near-term cash flow. - **Genentech collaboration partner** (primary) — Genentech pays royalties tied to Erivedge sales, which are Curis’s only foreseeable revenue source. - **Potential licensing partners** (primary) — Large pharma or biotech partners that could license emavusertib to fund development and commercialization. - **Clinical trial patients and investigators** (secondary) — Patients and trial sites participating in TakeAim studies that generate the clinical data needed for partnering. - **Capital markets investors** (primary) — Equity investors and financing providers that supply cash to support R&D and operations. - Genentech/Roche, which generates royalty revenue from Erivedge sales - Potential pharma partners that may license emavusertib - Clinical trial participants enrolled in TakeAim studies - Investors and capital providers funding ongoing R&D - Future commercial partners needed to fund development and launch ## Geography Curis is headquartered in the United States and its operating footprint is primarily U.S.-based because its clinical development, financing, and corporate functions are centered there. The company expects future royalty revenue from Erivedge sales in the U.S. and from Roche sales outside the U.S., so its cash flow is linked to both domestic and international commercialization. The filings also note exposure to international trade policy, including China-related supply chain and tariff risk, which matters because clinical development depends on timely access to materials and services. No country-level revenue table was disclosed in the provided excerpts, so the geographic picture is based on narrative disclosure rather than an authoritative revenue split. - Headquartered in the United States - Royalty revenue tied to Erivedge sales in the U.S. - Royalty revenue also tied to Roche sales outside the U.S. - Clinical development and corporate operations are U.S.-centric - Trade policy and China-related supply chain risk can affect development timelines ## Strategy Curis’s near-term strategy is to focus resources on emavusertib and generate clinical data strong enough to support partnering or licensing. Management explicitly identifies successful execution of current and planned clinical trials, favorable trial results, and additional financing as the main drivers of success. The company is also trying to preserve optionality through collaboration, which would shift some development and commercialization burden to a partner. At the same time, Curis is managing liquidity carefully because its operating results depend heavily on trial progress and external funding access. - **Execute emavusertib clinical trials** (short-term) — Clinical data is the main value driver and the basis for any future partnership or approval path. - **Secure additional financing** (short-term) — The company expects continued operating losses and needs capital to fund R&D and corporate overhead. - **Pursue collaboration or licensing for emavusertib** (medium-term) — A partner could provide non-dilutive funding and commercialization capability. - Advance emavusertib through TakeAim clinical trials - Generate data that supports partnering or licensing - Raise additional capital to fund operations - Use collaborations to share development and commercialization risk - Preserve cash while prioritizing the lead asset ## Risks Curis faces substantial execution risk because its future depends heavily on the clinical and commercial progress of a single lead asset, emavusertib. The company also disclosed going-concern and liquidity pressure, including the need to raise additional capital and the possibility that it may not regain or maintain Nasdaq listing compliance. Because Curis relies on royalty income from Erivedge and has sold a portion of those future royalties, cash generation is limited and partially encumbered. More broadly, biotechnology development carries high regulatory, trial, manufacturing, and partner-dependency risk, while trade policy, supply chain disruption, and FDA staffing or shutdown issues can delay development timelines. - **Single-asset dependence on emavusertib** [high] — Future operating results largely depend on the progress and outcome of one clinical program. - **Liquidity and going-concern pressure** [high] — The company expects substantial operating losses and must raise additional capital to fund operations. - **Nasdaq Capital Market non-compliance** [high] — Delisting would reduce trading liquidity, investor access, and capital-raising flexibility. - **Royalty concentration and encumbrance** [medium] — Foreseeable revenue comes from Erivedge royalties, but a significant portion is payable to Oberland. - **Regulatory and FDA disruption** [medium] — Delays in FDA guidance or review can slow trial progression and approval timelines. - Dependence on emavusertib creates single-asset concentration risk - Need for additional financing raises dilution and going-concern risk - Nasdaq non-compliance could reduce liquidity and access to capital - Royalty income depends on continued Erivedge commercialization - Royalty monetization diverts future cash flows to Oberland - FDA delays or regulatory changes can slow clinical development - Supply chain and tariff disruptions can affect trial materials and timelines ## Accounting Curis’s reported results are highly sensitive to judgment around royalty accounting, financing transactions, and the valuation of liabilities tied to future royalty sales. The company recognizes royalty revenue from Genentech’s Erivedge sales, but a substantial portion of those receipts is payable to the Oberland purchasers, so the accounting presentation must reflect both revenue recognition and the related liability. Because the business is clinical-stage, quarterly results can swing materially with R&D spending, trial timing, and stock-based compensation rather than with product sales. Investors should also pay attention to estimates and assumptions used for liabilities, including the put/call price under the royalty purchase agreement, as well as any going-concern disclosures and financing-related accounting. - **Royalty revenue and related liability accounting** — Affects reported revenue, liabilities, and cash flow presentation - **Fair value/estimate of royalty repurchase obligation** — Can materially affect balance sheet liabilities - **Clinical-stage R&D expense timing** — Creates significant quarter-to-quarter earnings volatility - **Going-concern assessment** — Important for evaluating liquidity and financial statement assumptions - Royalty revenue recognition depends on Genentech/Roche sales of Erivedge - A portion of royalty cash flows is diverted under the Oberland agreement - Royalty sale liability and put/call price require ongoing estimation - R&D expense is highly variable with clinical trial timing - Stock-based compensation affects G&A and R&D expense - Going-concern disclosures are important given recurring losses --- *Last updated: 2026-08-11T04:46:27.334333+00:00*